How does cannabis use complicate heart transplantation? | Research

The takeaway

A review found that cannabis interacts with critical transplant medications through shared metabolic pathways, potentially destabilizing immunosuppression and increasing risks of graft failure and infection in heart transplant recipients.

Transplant patients and clinicians navigating cannabis use in the context of organ transplantation, and anyone interested in how cannabis interacts with other medications.

Shared CYP-450 metabolism with transplant drugs

What the researchers found

THC and CBD are metabolized by cytochrome P-450 and P-glycoprotein, the same pathways used by calcineurin inhibitors essential for transplant immunosuppression. These drug-drug interactions, combined with variable cannabis product potency, make maintaining adequate immunosuppression unpredictable. Cannabis use has been associated with increased risk of graft failure and infections.

Why it matters

As cannabis becomes legal in more jurisdictions, transplant programs face growing inconsistency in how cannabis use affects candidacy. The pharmacological interactions with transplant drugs pose real clinical risks that go beyond the policy debate.

The numbers in context

THC and CBD metabolized by CYP-450 and P-glycoprotein; same pathways as calcineurin inhibitors; cannabis associated with graft failure and increased infection risk

How the study worked

In-depth narrative review synthesizing evidence on cannabinoid pharmacokinetics, drug-drug interactions with transplant medications, cannabis use disorder, and outcomes in transplant recipients.

What this study cannot tell us

Narrative review without systematic methodology. Limited direct evidence from transplant populations. Cannabis product variability makes generalizing pharmacological interactions difficult.

How to read the evidence

Narrative review synthesizing pharmacological evidence and limited clinical data from transplant populations.

When this study was published

Published in 2021; transplant guidelines regarding cannabis are still evolving.

The bigger picture

Cannabis legalization has created disparities in transplant candidacy, with some programs disqualifying cannabis users and others not. This review argues the pharmacological concerns are legitimate, but standardized guidelines are needed to ensure fairness in organ distribution.

Questions still open

Can transplant immunosuppression be safely managed in cannabis users with close monitoring? Should CBD products be treated differently from THC products in transplant candidacy decisions? How should transplant programs balance equity concerns with pharmacological risks?

Common questions

Why is cannabis a problem for transplant patients?

Cannabis is broken down by the same liver enzymes (CYP-450) used to metabolize immunosuppressive drugs. This overlap can cause unpredictable drug levels, potentially leading to organ rejection or toxic side effects.

Can transplant patients use CBD?

CBD also interacts with CYP-450 enzymes and P-glycoprotein. While often perceived as safer than THC, CBD carries similar risks for disrupting transplant medication levels.

Does cannabis use disqualify someone from a transplant?

Policies vary widely between transplant programs, creating disparities in candidacy. This review argues for standardized guidelines based on pharmacological evidence rather than inconsistent institutional policies.

Read the original research

The growing dilemma of legalized cannabis and heart transplantation.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 40(9), 863-871

View on PubMed ↗Publisher’s paper ↗

Citation

Olt, Caroline; Faulkenberg, Kathleen D; Hsich, Eileen M. (2021). The growing dilemma of legalized cannabis and heart transplantation.. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 40(9), 863-871. https://doi.org/10.1016/j.healun.2021.03.024